Home About Articles Contact

Lisa Astor

Strategic Healthcare Content Expert | Editorial Leadership | Creative Communications Driver

ASCO AI in Oncology •

AI-Selected Predictive Biomarker Guides First-Line Treatment Selection in Advanced Pancreatic Cancer

A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy options for patients with advanced pancreatic cancer, according to the results of a study presented in a poster at the 2026 ASCO Gastrointestinal Cancers Symposium.A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy option...
The ASCO Post •

Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma

In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with heavily pretreated relapsed or refractory multiple myeloma. These patients remained progression-free for at least 5 years after a single infusion of ciltacabtagene autoleucel without any subsequent or maintenance treatment.
Targeted Oncology •

Riding the Wave of Chemoimmunotherapy: A New Era in Endometrial Cancer Management

According to Brian Slomovitz, MD, “immunotherapy has activity and [provides] a benefit in all women with endometrial cancer.” Slomovitz, division director of gynecologic oncology at Mount Sinai Medical Center, professor of obstetrics and gynecology at Florida International University, and clinical trial lead for uterine cancers at the GOG Foundation, told Targeted Therapies in Oncology that especially for patients with deficient mismatch repair (dMMR) endometrial tumors, immunotherapy has result...
Targeted Oncology •

New HER2-Low Subgroup Expands Utility of HER2-Targeted Therapies

One of the biggest shifts in the oncology field from the past year was the introduction of HER2-low into clinical practice. Patients with breast cancer have typically been divided by subtype according to HER2 positivity or negativity, but emerging evidence suggests that there is now room and treatment options available for a third group of patients that was previously ignored, those characterized with HER2-low disease.HER2 positivity is considered overexpression of HER2 as assessed by an immunoh...
Targeted Oncology •

Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?

Newer treatment modalities are changing the landscape for patients with relapsed or refractory multiple myeloma who have received multiple prior therapies. Chimeric antigen receptor (CAR) T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic. As such, many questions remain about the optimal sequence and usage of these agents across the course o...
Targeted Oncology •

FDA Cracks Down on Dangling Accelerated Approvals in 2021, Pathway Is Scrutinized

This article explores how 10 immunotherapy indications came under question in 2021 after failing to demonstrate clinical benefits in confirmatory trials. Learn about the FDA's tightened oversight and its impact on the availability of certain immunotherapy treatments in the US market, highlighting the delicate balance between rapid access to promising therapies and ensuring proven clinical efficacy.